Filing Summary
Company: XTL Biopharmaceuticals Ltd. Filing: Form 6-K, filed for October 2026; dated October 14, 2026.
Business Context and Reporting Period
This Form 6-K reports a board change. It does not provide business or operating updates for a financial reporting period.
Financial Results and Liquidity
The filing contains no revenue, profit, cash flow, margin, debt, liquidity, or other financial performance figures.
Material Changes
- On October 12, 2026, external director Iris Shapira Yalon notified the Company of her resignation for personal reasons. It is effective upon the earlier of the appointment of her successor by shareholders or November 20, 2026.
- The Company stated that her resignation did not result from any disagreement concerning the Company’s operations, policies, or practices.
- On October 14, 2026, the Board approved the nomination of Gilai Dolev to replace her as an external director for an initial three-year term, subject to shareholder approval.
Outlook, Conditions, and Risks
The Company intends to convene a shareholder meeting to vote on Mr. Dolev’s election under the applicable Israeli Companies Law requirement. The meeting date and outcome are not provided; the Company said it would furnish the meeting notice and proxy statement to the SEC on Form 6-K.
Important Facts to Verify
- Whether shareholders approve Mr. Dolev’s election and the date of the vote.
- When Ms. Shapira Yalon’s resignation becomes effective.
- Whether the Company subsequently files the meeting notice and proxy statement.